V. Shi

发表

Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE

Akshay S. Desai, S. Solomon, A. Desai, 2021, Clinical Research in Cardiology.

Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696

S. Solomon, J. McMurray, P. Jhund, 2014, Circulation. Heart failure.

Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.

S. Solomon, J. McMurray, P. Jhund, 2016, Circulation. Heart failure.

Geographic variations in the PARADIGM-HF heart failure trial

S. Solomon, J. McMurray, K. Swedberg, 2016, European heart journal.

The effects of high‐dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy

M. Lefkowitz, V. Shi, V. Arora, 2007, Blood pressure. Supplement.

Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM‐HF analysis

Akshay S. Desai, S. Solomon, A. Desai, 2021, European journal of heart failure.

Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan

Akshay S. Desai, S. Solomon, M. Pfeffer, 2021, Circulation. Heart failure.

Impact of systolic blood pressure on the safety and tolerability of initiating and up‐titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study

R. Wachter, J. McMurray, M. Senni, 2018, European journal of heart failure.

Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial

Akshay S. Desai, S. Solomon, A. Desai, 2016, Circulation. Heart failure.

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.

Akshay S. Desai, S. Solomon, A. Desai, 2016, Circulation. Heart failure.

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection FractionCLINICAL PERSPECTIVE

Akshay S. Desai, S. Solomon, A. Desai, 2016 .

SUPPLEMENTAL MATERIAL Factors Associated with Noncompletion During the Run ‐ in Period Prior to Randomization and the Efficacy of LCZ 696 in the PARADIGM ‐ HF Trial

S. Solomon, A. Desai, J. McMurray, 2016 .

Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.

Sanjiv J. Shah, S. Solomon, M. Pfeffer, 2020, Hypertension.

Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial.

Akshay S. Desai, S. Solomon, A. Desai, 2016, JACC. Heart failure.

Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).

S. Solomon, J. McMurray, K. Swedberg, 2016, Circulation.

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF

S. Solomon, J. McMurray, K. Swedberg, 2017, European heart journal.

Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial

Akshay S. Desai, S. Solomon, M. Pfeffer, 2021, Circulation. Heart failure.

S. Solomon, J. McMurray, K. Swedberg, 2016, Circulation.

Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction

S. Solomon, M. Pfeffer, J. McMurray, 2020, Circulation.

A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction

S. Solomon, J. McMurray, P. Jhund, 2020, European Heart Journal.

The effects of sacubitril/valsartan on coronary outcomes in PARADIGM‐HF

S. Solomon, J. McMurray, K. Swedberg, 2017, American heart journal.

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial

Akshay S. Desai, S. Solomon, A. Desai, 2016, European journal of heart failure.

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

Akshay S. Desai, S. Solomon, A. Desai, 2015, Circulation.

Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.

S. Solomon, J. McMurray, K. Swedberg, 2015, The New England journal of medicine.

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial

Akshay S. Desai, S. Solomon, A. Desai, 2019, European journal of heart failure.

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

Akshay S. Desai, Sanjiv J. Shah, S. Solomon, 2019, The New England journal of medicine.

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

G. Bakris, B. Pitt, V. Shi, 2010, The Lancet.

Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF.

Sanjiv J. Shah, S. Solomon, M. Pfeffer, 2019, Journal of the American College of Cardiology.

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.

Akshay S. Desai, S. Solomon, A. Desai, 2018, JACC. Heart failure.

Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study

J. Tuomilehto, G. Bakris, B. Pitt, 2008, Blood pressure.

Exceptional early blood pressure control rates: The ACCOMPLISH trial

W. Cushman, G. Bakris, B. Pitt, 2007, Blood pressure.

The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.

G. Bakris, B. Pitt, V. Shi, 2008, Journal of the cardiometabolic syndrome.

Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk

S. Nesbitt, G. Bakris, B. Pitt, 2007, Blood pressure.

Four aces of heart failure therapy: systematic review of established and emerging therapies for heart failure with reduced ejection fraction

M. Senni, V. Shi, E. D’Elia, 2022, Cardiology Plus.

MINI-FOCUS ISSUE: HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)

Akshay S. Desai, Eld, S. Solomon, 2022 .

Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.

Akshay S. Desai, S. Solomon, A. Desai, 2015, Journal of the American College of Cardiology.

Natriuretic peptide‐based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON‐HF

S. Solomon, M. Pfeffer, J. McMurray, 2022, European journal of heart failure.

Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.

S. Solomon, J. McMurray, K. Swedberg, 2019, Journal of the American College of Cardiology.

Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.

Sanjiv J. Shah, S. Solomon, M. Pfeffer, 2020, JACC. Heart failure.

Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impa

Akshay S. Desai, S. Solomon, A. Desai, 2018, Circulation. Heart failure.

Systolic Blood Pressure, Sacubitril/Valsartan, and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: PARAGON-HF

M. Vaduganathan, F. Zannad, B. Pieske, 2020 .

Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF.

Akshay S. Desai, S. Solomon, A. Desai, 2019, Journal of the American College of Cardiology.

Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.

Akshay S. Desai, S. Solomon, A. Desai, 2017, The lancet. Diabetes & endocrinology.

Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients with Heart Failure and Reduced Ejection Fraction:PARADIGM-HF.

Akshay S. Desai, S. Solomon, A. Desai, 2019, Circulation.

Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial.

Akshay S. Desai, S. Solomon, A. Desai, 2016, JACC. Heart failure.

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF

Akshay S. Desai, S. Solomon, A. Desai, 2017, European journal of heart failure.

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial

Akshay S. Desai, S. Solomon, A. Desai, 2021, European journal of heart failure.

Seferovic, J. P. et al. (2017) Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes

Akshay S. Desai, A. Desai, J. McMurray, 2017 .

Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial

D. Atar, S. Solomon, M. Pfeffer, 2018, Circulation. Heart failure.

Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM‐HF

Akshay S. Desai, S. Solomon, A. Desai, 2017, Journal of the American Heart Association.

Abstract 17948: Reduced Loop Diuretic Use in Patients Taking Sacubitril/Valsartan Compared With Enalapril: The Paradigm-HF Study

S. Solomon, J. McMurray, K. Swedberg, 2016 .

Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection FractionCLINICAL PERSPECTIVE

S. Solomon, J. McMurray, P. Jhund, 2016 .

B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.

Akshay S. Desai, S. Solomon, A. Desai, 2019, Journal of the American College of Cardiology.

IGFBP7 (Insulin-Like Growth Factor–Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure

S. Solomon, J. McMurray, A. Shah, 2018, Circulation. Heart failure.

The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial

S. Solomon, J. McMurray, A. Shah, 2012 .

Global differences in heart failure with preserved ejection fraction: the paragon-hf trial

S. Solomon, J. McMurray, P. Jhund, 2020 .

Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas

Akshay S. Desai, S. Solomon, A. Desai, 2018, European journal of heart failure.

CARDIOVASCULAR AND RENAL OUTCOMES OF MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN PARAGON-HF

Sanjiv J. Shah, S. Solomon, M. Pfeffer, 2020 .

Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.

M. Senni, V. Shi, A. Kaplan, 2018, International journal of cardiology.

Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction

J. McMurray, K. Swedberg, J. Rouleau, 2020, European journal of heart failure.

Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial.

S. Solomon, M. Pfeffer, J. McMurray, 2021, JACC. Heart failure.

A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction

S. Solomon, J. McMurray, P. Jhund, 2020, European heart journal.

248Effect of sacubitril/valsartan on plasma biomarkers that reflect extracellular matrix regulatory mechanisms and collagen synthesis in patients with heart failure and reduced ejection fraction

S. Solomon, K. Swedberg, J. Rouleau, 2017 .

MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND LEFT VENTRICULAR EJECTION FRACTION≥45%: INSIGHTS FROM PARAGON-HF

S. Solomon, M. Pfeffer, A. Desai, 2020 .

LOW URINARY CGMP/BNP RATIO IS ASSOCIATED WITH WORSE OUTCOMES IN HEART FAILURE BUT IS INCREASED BY TREATMENT WITH SACUBITRIL/VALSARTAN: AN ANALYSIS OF PARADIGM-HF

S. Solomon, J. McMurray, K. Swedberg, 2017 .

Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure

M. Pfeffer, J. McMurray, K. Swedberg, 2022, European journal of heart failure.

Experimental models of graft arteriosclerosis.

V. Shi, B. Soleimani, 2006, Methods in molecular biology.

Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization.

Akshay S. Desai, S. Solomon, A. Desai, 2016, Journal of the American College of Cardiology.

Impaired left atrial function in heart failure with preserved ejection fraction

J. McMurray, A. Shah, M. Zile, 2014, European journal of heart failure.

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Akshay S. Desai, S. Solomon, A. Desai, 2014, The New England journal of medicine.

Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.

Akshay S. Desai, A. Desai, J. McMurray, 2022, JAMA cardiology.

Pharmacokinetics of Valsartan in Pediatric and Adolescent Subjects With Hypertension

V. Shi, G. Sunkara, J. Blumer, 2009, Journal of clinical pharmacology.

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

G. Bakris, B. Pitt, V. Shi, 2008, The New England journal of medicine.

Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction

Sanjiv J. Shah, S. Solomon, M. Pfeffer, 2019, Circulation.

IMPACT OF CARDIOVASCULAR AND NON-CARDIOVASCULAR HOSPITALIZATION ON QUALITY OF LIFE IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

Akshay S. Desai, S. Solomon, J. McMurray, 2020 .

Efficacy and Safety of the Angiotensin Receptor Blocker Valsartan in Children With Hypertension Aged 1 to 5 Years

J. Flynn, A. Bagga, V. Shi, 2008, Hypertension.

Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis.

Akshay S. Desai, S. Solomon, J. McMurray, 2020, JACC. Heart failure.

S. Solomon, M. Pfeffer, J. McMurray, 2019, JACC. Heart failure.

Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

Akshay S. Desai, S. Solomon, J. McMurray, 2014, European journal of heart failure.

Akshay S. Desai, S. Solomon, K. Swedberg, 2016, Circulation. Heart failure.

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction

S. Solomon, J. McMurray, M. Zile, 2015, European journal of heart failure.

Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF

Akshay S. Desai, S. Solomon, M. Pfeffer, 2020, European journal of heart failure.

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

Akshay S. Desai, S. Solomon, J. McMurray, 2014, European heart journal.

Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.

Sanjiv J. Shah, R. Wachter, A. Baldridge, 2021, JAMA.

Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.

S. Solomon, J. McMurray, M. Vaduganathan, 2020, Journal of the American College of Cardiology.

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial

Sanjiv J. Shah, R. Wachter, M. Cowie, 2020, ESC heart failure.

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial

Akshay S. Desai, S. Solomon, J. McMurray, 2017, JAMA cardiology.

Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy

S. Solomon, J. McMurray, K. Swedberg, 2016, Circulation. Heart failure.

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.

Akshay S. Desai, S. Solomon, J. McMurray, 2015, European heart journal.

S. Solomon, J. McMurray, K. Swedberg, 2016, European journal of heart failure.

McMurray, J. J. V. et al. (2014) Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-

Akshay S. Desai, S. Solomon, J. McMurray, 2014 .

The Efficacy and Safety of Valsartan in Obese and Non‐Obese Pediatric Hypertensive Patients

V. Shi, K. Meyers, S. Solar-Yohay, 2011, Journal of clinical hypertension.

Tegaserod Does not Alter Fasting or Meal-Induced Biliary Tract Motility

W. Chey, R. Fisher, C. Beglinger, 2004, American Journal of Gastroenterology.

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

S. Solomon, J. McMurray, A. Shah, 2012, The Lancet.

Global Differences in Heart Failure With Preserved Ejection Fraction

S. Solomon, M. Pfeffer, J. McMurray, 2021, Circulation. Heart failure.

Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial

Akshay S. Desai, S. Solomon, J. McMurray, 2018, JAMA cardiology.

Akshay S. Desai, S. Solomon, J. McMurray, 2017, Circulation. Heart failure.

Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.

S. Solomon, J. McMurray, K. Swedberg, 2019, JACC. Heart failure.

Sacubitril/Valsartan (LCZ696) in Heart Failure.

J. McMurray, M. Lefkowitz, V. Shi, 2016, Handbook of experimental pharmacology.

Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.

Akshay S. Desai, S. Solomon, J. McMurray, 2016, Journal of the American College of Cardiology.

Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial

S. Solomon, J. McMurray, P. Jhund, 2014, European journal of heart failure.

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Akshay S. Desai, S. Solomon, J. McMurray, 2019, Circulation.

Clinical and Demographic Characteristics of Children With Hypertension

J. Flynn, V. Shi, S. Solar-Yohay, 2012, Hypertension.

Effectiveness and Safety of Valsartan in Children Aged 6 to 16 Years With Hypertension

M. Litwin, V. Shi, J. Blumer, 2011, Journal of clinical hypertension.

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF

Akshay S. Desai, S. Solomon, J. McMurray, 2015, European heart journal.

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.

Akshay S. Desai, S. Solomon, M. Pfeffer, 2017, JACC. Heart failure.

Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction

Sanjiv J. Shah, R. Wachter, M. Cowie, 2021, European journal of heart failure.

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction

S. Solomon, J. McMurray, F. Zannad, 2021, Journal of the American Heart Association.

THE ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI), SACUBITRIL/VALSARTAN, IMPROVES LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (PARAMOUNT TRIAL)

S. Solomon, J. McMurray, T. Biering-Sørensen, 2018 .

What is the impact of Tegaserod on gallbladder emptying?

R. Fisher, A. Lembo, V. Shi, 2003, American Journal of Gastroenterology.

Akshay S. Desai, M. Pfeffer, J. McMurray, 2022, European journal of heart failure.

Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations

Sanjiv J. Shah, C. O'connor, C. Yancy, 2017, Circulation. Heart failure.

Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the Week.

Jonathan H Seltzer, I. Piña, A. Jaffe, 2021, Journal of the American College of Cardiology.

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.

Akshay S. Desai, S. Solomon, J. McMurray, 2015, European heart journal.

Abstract 17986: Is There Really an “Obesity Paradox” in Heart Failure? An Analysis of PARADIGM-HF

Akshay S. Desai, S. Solomon, J. McMurray, 2016 .

The n e w e n g l a n d j o u r n a l of m e d i c i n e

Akshay S. Desai, J. Rouleau, M. Zile, 2014 .

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Akshay S. Desai, S. Solomon, J. McMurray, 2014, The New England journal of medicine.

S. Solomon, J. McMurray, P. Jhund, 2014, European journal of heart failure.

Impaired left atrial function in heart failure with preserved ejection fraction

J. McMurray, A. Shah, M. Zile, 2014, European journal of heart failure.

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.

Akshay S. Desai, S. Solomon, J. McMurray, 2018, JACC. Heart failure.

Akshay S. Desai, S. Solomon, J. McMurray, 2017, Circulation. Heart failure.

Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization.

Akshay S. Desai, S. Solomon, J. McMurray, 2016, Journal of the American College of Cardiology.

CONSISTENT BENEFIT OF SACUBITRIL/VALSARTAN OVER ENALAPRIL, IRRESPECTIVE OF BACKGROUND THERAPY IN PARADIGM-HF

S. Solomon, J. McMurray, K. Swedberg, 2016 .